{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Low+dose+Placebo&page=20",
    "query": {
      "intervention": "Low dose Placebo",
      "page": 20
    },
    "page_size": 10
  },
  "pagination": {
    "page": 20,
    "page_size": 10,
    "total_count": 1765,
    "total_pages": 177,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Low+dose+Placebo&page=21&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Low+dose+Placebo&page=19&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-22T13:35:48.175Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04523220",
      "title": "Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "End-stage Renal Disease",
        "Prevention of Thromboembolic Events",
        "Hemodialysis",
        "Hemodiafiltration"
      ],
      "interventions": [
        {
          "name": "BAY1213790 (Osocimab)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 704,
      "start_date": "2020-08-28",
      "completion_date": "2022-05-30",
      "has_results": true,
      "last_update_posted_date": "2023-07-21",
      "last_synced_at": "2026-11-22T13:35:48.175Z",
      "location_count": 26,
      "location_summary": "Azusa, California • Brawley, California • Encino, California + 21 more",
      "locations": [
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Brawley",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04523220"
    },
    {
      "nct_id": "NCT02064010",
      "title": "A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Drug-induced Tardive Dyskinesia"
      ],
      "interventions": [
        {
          "name": "SNC-102",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Synchroneuron Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2014-02",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2021-04-13",
      "last_synced_at": "2026-11-22T13:35:48.175Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02064010"
    },
    {
      "nct_id": "NCT01487460",
      "title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dyslipidemia",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "TAP311",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 137,
      "start_date": "2011-11",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2020-12-21",
      "last_synced_at": "2026-11-22T13:35:48.175Z",
      "location_count": 1,
      "location_summary": "Miramar, Florida",
      "locations": [
        {
          "city": "Miramar",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01487460"
    },
    {
      "nct_id": "NCT05759208",
      "title": "The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "OK-101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Okyo Pharma Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2023-04-28",
      "completion_date": "2023-12-15",
      "has_results": false,
      "last_update_posted_date": "2024-02-09",
      "last_synced_at": "2026-11-22T13:35:48.175Z",
      "location_count": 6,
      "location_summary": "Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 3 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Shelby",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05759208"
    },
    {
      "nct_id": "NCT01585168",
      "title": "Functional Neuroimaging of Alcoholism Vulnerability (PIT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Memantine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 71,
      "start_date": "2011-12",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2021-03-16",
      "last_synced_at": "2026-11-22T13:35:48.175Z",
      "location_count": 1,
      "location_summary": "Hartford, Connecticut",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01585168"
    },
    {
      "nct_id": "NCT06774625",
      "title": "This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Molars",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Pain, Postoperative"
      ],
      "interventions": [
        {
          "name": "LTG-001 High Dose",
          "type": "DRUG"
        },
        {
          "name": "LTG-001 Mid Dose",
          "type": "DRUG"
        },
        {
          "name": "LTG-001 Low Dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Suzetrigine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Latigo Biotherapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 250,
      "start_date": "2024-12-19",
      "completion_date": "2025-08-08",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-11-22T13:35:48.175Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06774625"
    },
    {
      "nct_id": "NCT01203150",
      "title": "Effects of Exercise in People With Paraplegia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Spinal Cord Injury"
      ],
      "interventions": [
        {
          "name": "Exercise",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 32,
      "start_date": "2008-10",
      "completion_date": "2012-09",
      "has_results": false,
      "last_update_posted_date": "2015-03-24",
      "last_synced_at": "2026-11-22T13:35:48.175Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01203150"
    },
    {
      "nct_id": "NCT03608397",
      "title": "Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cervical Dystonia"
      ],
      "interventions": [
        {
          "name": "DaxibotulinumtoxinA for injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Revance Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 301,
      "start_date": "2018-06-20",
      "completion_date": "2020-06-16",
      "has_results": false,
      "last_update_posted_date": "2022-12-05",
      "last_synced_at": "2026-11-22T13:35:48.175Z",
      "location_count": 44,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 38 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03608397"
    },
    {
      "nct_id": "NCT03978520",
      "title": "A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus (SLE)"
      ],
      "interventions": [
        {
          "name": "Elsubrutinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo for elsubrutinib",
          "type": "DRUG"
        },
        {
          "name": "Upadacitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo for upadacitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 341,
      "start_date": "2019-07-25",
      "completion_date": "2022-07-14",
      "has_results": true,
      "last_update_posted_date": "2023-07-21",
      "last_synced_at": "2026-11-22T13:35:48.175Z",
      "location_count": 47,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Jonesboro, Arkansas + 40 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03978520"
    },
    {
      "nct_id": "NCT00973024",
      "title": "A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Low Back Pain",
        "Low Back Pain, Recurrent"
      ],
      "interventions": [
        {
          "name": "JNJ-42160443 3 mg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-42160443 1 mg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-42160443 6 mg/3mg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-42160443 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 389,
      "start_date": "2009-09",
      "completion_date": "2011-05",
      "has_results": false,
      "last_update_posted_date": "2016-06-06",
      "last_synced_at": "2026-11-22T13:35:48.175Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Pismo Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00973024"
    }
  ]
}